Chicago—Results of a study including more than 1,000 eyes followed for up to 3 years show that selective laser trabeculoplasty (SLT) performed with the Q-switched frequency-doubled 532-nm Nd:YAG laser (Selecta II, Lumenis) is a safe and effective option for lowering and maintaining IOP across a spectrum of glaucoma patients, reported Lawrence F. Jindra, MD, at the annual meeting of the American Academy of Ophthalmology.
Chicago—A consortium of German researchers is making considerable progress toward development of an implantable device for 24-hour monitoring of IOP, according to Peter Walter, MD.
American ophthalmologists have a number of meetings each year they can choose to attend to hear the latest advances in the practice of eye care.
Lisbon, Portugal—The results of the 7th annual survey on foldable IOLs indicate that dislocation and decentration are the most common reasons for lens explantation, with incorrect lens power the next most important factor.
In the continual quest for a better understanding of vision, the Wilmer Eye Institute at Johns Hopkins University School of Medicine, Baltimore, is presenting its annual Current Concepts in Ophthalmology series.
Vienna, Austria—A sharp posterior optic edge design seems to be superior to a double round optic edge design in preventing posterior capsule opacification (PCO). Investigators reported significantly less PCO at 1, 2, and 3 years after implantation of the Sensar OptiEdge AR40e IOL compared with the Sensar AR40 model (both from AMO).
The development of IOLs has come full circle. In 1949, Sir Harold Ridley attempted to emulate the curvature and size of the natural lens with the development of the Ridley IOL. In subsequent years, the focus was on IOL mechanical issues, materials, and optics. Today, with wavefront technology, researchers are going back to the beginning and are attempting to emulate some of the more subtle features of the natural lens.
Rogers, AR—The recent approval of the Tecnis IOL (AMO) on an acrylic platform gives cataract surgeons another option in an expanding menu of choices, said Randy Cole, MD, FACS, who is medical director and founder of Boozman-Hof Eye Surgery and Laser Center, Rogers, AR.
Irvine, CA—Allergan Inc. has offered to acquire Inamed Corp. for $1.45 billion cash and 17.9 million shares of Allergan stock to create a global leader in medical aesthetics.